Skip to main content
. Author manuscript; available in PMC: 2018 Jan 3.
Published in final edited form as: Vaccine. 2016 Nov 23;35(1):164–169. doi: 10.1016/j.vaccine.2016.11.012

Table 3.

Clinician Barriers to HPV vaccination (N=280)

How strongly would you agree or disagree that the following are barriers related to immunizing your patients against HPV? Disagree, % Neither Disagree/Agree, % Agree, % Missing, %
Your concerns about vaccine safety 45.4 10.7 43.2 0.7
Your concerns about vaccine efficacy 63.2 18.9 17.9 0
Discussing sexuality/sexually transmitted infections 42.1 14.6 41.8 1.4
Vaccinated teens practicing riskier sexual behaviors 61.8 18.2 20.0 0
Administering a new vaccine with a limited track record of safety 42.9 15.4 41.8 0
Adding another vaccine to the vaccine schedule 41.8 14.6 43.6 0
Lack of information about the HPV vaccine 58.6 16.4 24.6 0.4
The upfront cost of purchasing private stock HPV vaccine 62.1 26.8 10.4 0.7
The cost of stocking HPV vaccine 67.9 25.4 6.4 0.4
Lack of adequate reimbursement for HPV vaccination 65.0 27.1 7.1 0.7
Failure of some insurance companies to cover the cost of vaccination 51.8 24.3 23.6 0.4
The time it takes to discuss HPV vaccination with patients and/or parents 54.3 16.4 28.9 0.4
Difficulty ensuring that patients will complete the 3-dose HPV vaccination series 38.2 20.0 41.4 0.4
HPV vaccination is not required for school attendance 29.3 20.0 50.4 0.4

Abbreviations: HPV, Human Papillomavirus